top of page
Browse by category
Search
D&D Pharmatech completes enrolment in trial evaluating DD01 Dual GLP-1/Glucagon receptor agonist for MASH
D&D Pharmatech has completed patient enrolment in DD01-DN-2, an ongoing Phase 2 trial designed to evaluate the efficacy and safety of...
Helix launches world's largest clinico-genomic cohort of GLP-1 agonist treated
Helix has launched a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1)...
Micronutrient deficiencies are common in people with type 2 diabetes
Micronutrient deficiencies are common in people with type 2 diabetes, according to the findings of a pooled data analysis of the...
TNF Pharmaceuticals initiates study evaluating TNF-alpha inhibitor isomyosamine in preserving lean muscle mass after GLP-1
TNF Pharmaceuticals has initiated the first in a series of studies to evaluate the impact of its novel oral TNF-alpha (TNF-α) inhibitor...
Napo Pharmaceuticals files patent application for crofelemer to mitigate GLP-1 side-effects
Napo Pharmaceuticals has filed a broad defining provisional patent application with the US Patent and Trademark Office (USPTO) for...
RYGB and SG lower health care costs for T2DM patients
In patients with type 2 diabetes, Roux-en-Y gastric bypass and sleeve gastrectomy for weight loss may be effective for reducing long-term...
Browse by tag
bottom of page